MENU Close
Close
  • Home
  • Services
  • Attorneys
  • Resources
  • News & Events
  • About Us
  • Contact Us
  • Join our Team
Search
Back
    Quick Links:
    Join Webinar
    Read News
    Our Location
    A
    Alternative Dispute ResolutionAntitrust & Trade RegulationAppellate Practice
    B
    Banking & Financial ServicesBankruptcy, Creditors’ Rights, and Financial RestructuringBeer LawBusiness Law
    C
    Cannabis LawConstruction LawCriminal Defense
    E
    Economic Development LawElder Care & Special Needs LawElectronic Discovery ("E-Discovery")Environmental LawEstate Planning and Administration & Wealth PreservationExecutive Compensation, Employment, ERISA, and Employee Benefits
    F
    Food, Beverage & HospitalityFranchise Law
    H
    Health Care & Life SciencesHealth Care ProvidersHigher EducationHospitals and Health Networks
    I
    ImmigrationInsurance CoverageIntellectual PropertyIntellectual Property Litigation, Arbitration, and Dispute ResolutionIntellectual Property Portfolio Strategy, Management & LicensingInternational BusinessInternet Law
    L
    Labor & EmploymentLiquor Law, Licensing, Manufacturing, and DistributionLitigation
    M
    Media LawMergers & AcquisitionsMunicipal Law
    N
    Non-Profit Law
    P
    Patent Preparation and ProsecutionPharmaceutical / Medical Devices / Pharma ServicesProducts and Consumer Liability DefenseProfessional LiabilityPublic Utilities
    R
    Real Estate, Finance, and Land Use
    S
    SecuritiesSolar Energy
    T
    TaxationTelecommunicationsTrademark & Copyright Protection & Enforcement
    V
    Venture Tech & Emerging Growth Companies
    W
    White Collar Investigations & DefenseWorkers’ Compensation
    • New Jersey
    • New York
    • Pennsylvania
    • Blogs
    • Articles
    • Podcasts
    • COVID-19 Resources
    • News
    • Events
    • Webinars
    • About Us
    • Delivering Value
    • Diversity & Inclusion
    • Meritas

    New Jersey

    400 Crossing Boulevard
    8th Floor
    Bridgewater, NJ 08807
    Phone:(908) 722-0700
    Fax:(908) 722-0755

    28 Valley Road
    Suite 1
    Montclair, NJ 07042

    New York

    7 Times Square
    21st Floor
    New York City, NY 10036
    Phone:(212) 808-0700
    Fax:(212) 808-0844

    Pennsylvania

    515 West Hamilton Street
    Suite 502
    Allentown, PA 18101
    Phone:(610) 391-1800
    Fax:(610) 391-1805

    • What sets us apart
    • Attorneys
    • Other Professionals
    • Professional Development
    • Non-Discrimination Policy

    Categories

    Banking Compliance Environmental Food, Beverage & Hospitality General Business Health Care In The News Insurance Labor & Employment Laws Legislation Patents Real Estate Regulatory Tax Trademarks
    Blogs > Legally Grown > Cannabis Businesses Selling CBD and...
    Norris McLaughlin Cannabis Law Group
    Visit Profile

    Cannabis Businesses Selling CBD and Hemp Products: A Target for FDA and FTC

    Cannabis Businesses Selling CBD and Hemp Products: A Target for FDA and FTC

    As one might expect from the title “Federal Food, Drug, and Cosmetic Act,” the Food and Drug Administration (“FDA”) has broad authority.

    Introduction

    Since the approval of the drug EPIDIOLEX® CV, which has cannabidiol (“CBD”) as an active ingredient, the FDA has taken the position that some products containing CBD are unapproved drugs or unapproved dietary supplements. Rooted Apothecary LLC (“Rooted”) has just drawn the ire of the FDA and the Federal Trade Commission (“FTC”) for its CBD‑containing products.

    The FDA’s Letter

    Rooted offers “Rebelliously Wholesome Remedies” and “Full Spectrum CBD Products.” While being “rebellious” is not a great start in avoiding the regulators, Rooted asserts that “[r]esearch from around the world has proven CBD to be safe, powerful, and effective for helping your body manage emotional, mental, and physical stress.”

    In a letter dated October 10, 2019, the FDA disagreed, stating that “[t]here are many unanswered questions about the science, safety, effectiveness, and quality of unapproved products containing CBD.” Regarding Rooted’s CBD‑containing hemp capsules and hemp oil, the FDA took the position that Rooted was offering the products as dietary supplements contrary to law. The fact that the FDA has approved CBD in the form of EPIDIOLEX® CV is critical for this determination.

    Similarly, the FDA took the position that Rooted’s hemp oil and some other products are unapproved new drugs. The fact that Rooted described medical benefits with which CBD “may be” associated rather than “are” associated, was insufficient to shield Rooted from FDA scrutiny.

    The FDA also alleged that Rooted’s products are misbranded because “their labeling fails to bear adequate directions for use.” As the kicker, Rooted had allegedly made unsubstantiated advertising claims contrary to the FTC Act. Specifically, “[t]he FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence.”

    The FDA gave Rooted 15 days to correct the violations, a very short time frame in which to reorganize an entire business. Interestingly, Rooted asserts that products described on its Internet site “contain a value of 0.3% or less [tetrahydrocannabinol (“THC”)] . . . .” If true, the distribution of Rooted’s products is legal under the 2018 Farm Bill’s amendments to the Controlled Substance Act. However, it is the specific uses of the products that concern the FDA.

    Take‑Home Messages

    It is likely that its health‑related claims made Rooted an FDA target.  In particular, Rooted’s statements as to the safety of CBD for children may have been the tipping point. It is clear that if you are going to make a claim, you’d better have reports to back up the claim.  And using the word “may” is not enough to make a claim legitimate. Making unsubstantiated claims may also give rise to civil lawsuits. Even though the trend for CBD‑containing products is rampant and the market seems a free‑for‑all, it is clear that the FDA and the FTC are monitoring activity. In short, it seems that making unsubstantiated health‑related claims is an easy way to put a cannabis company at risk.

    If you have any questions about this post or any other related matters, please feel free to contact our Cannabis Law Practice Group.
    Norris McLaughlin Cannabis Law Group
    Visit Profile

    Related Posts

    New York City Department of Health Begins Embargoing CBD Food and Beverages FDA Emphasizes Its Commitment to “Sound, Science-based Policy” for CBD Products What Cannabis Brand Owners Need to Know About the USPTO's Recent Guidance on Cannabis Trademarks

    Share

    Tags

    #cannabis products #FDA Regulation #FTC

    Similar Posts

    April 28, 2023
    New Jersey Regulators Reverse and Renew Curaleaf’s License with Conditions
    New Jersey Regulators Reverse and Renew Curaleaf’s License with Conditions
    February 17, 2023
    Delta-What??!!- Delta-8 and Delta-9 Create High Anxiety for Policymakers
    Delta-What??!!- Delta-8 and Delta-9 Create High Anxiety for Policymakers
    January 5, 2023
    Cannabis Lounges Coming to New Jersey
    Cannabis Lounges Coming to New Jersey

    Helpful links

    • About Us
    • News
    • Services
    • Blogs
    • Attorneys
    • Articles
    • (COVID-19)
    • Events
    • Join our Team
    Connect

    Connect with Us

    • LinkedIn
    • Facebook
    • Twitter
    • Instagram
    • Youtube

    Join our growing team

    We are looking for quality attorneys to help us do more for our clients. At Norris McLaughlin, each attorney has the same opportunity to succeed whether you’re at the beginning of a career or pinnacle of the profession.

    Learn More

    Subscribe to our content

    Receive timely legal information delivered to your inbox

    This field is for validation purposes and should be left unchanged.
    © , Norris McLaughlin, P.A., All Rights Reserved. Attorney Advertising.
    VIEW OUR DISCLAIMER,  TERMS OF USE,  AND PRIVACY POLICY

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume you consent to our cookie policy. Learn more